Allergic rhinitis: the “Ghost Diagnosis” in patients with asthma

Juan Carlos Ivancevich Friday, 18 September 2015 19:47
Open Access
Review

Maureen Egan and Supinda Bunyavanich

Abstract

Allergic rhinitis (AR) is a common comorbidity of asthma that contributes to asthma severity. Although over 80 % of asthmatics have AR, the condition is frequently underdiagnosed in subjects with asthma. AR itself is also a highly prevalent condition, affecting 10-30 % of adults and up to 40 % of children. AR has been associated with both increased risk of asthma development and asthma severity. The exact mechanisms underlying these relationships have yet to be fully elucidated, but evidence supports a role for allergen sensitization. Compared to those with asthma alone, patients with comorbid AR and asthma have greater use of health care resources, including visits to the general practitioner, emergency department and hospitalizations. Pharmacological treatment of AR reduces this health care burden. Immunotherapy for AR improves both asthma and rhinitis symptoms in addition to preventing future allergen sensitizations and asthma development. Appropriate recognition, diagnosis and treatment of AR can significantly reduce asthma morbidity and improve quality of life.

Psychological aspects in asthma: do psychological factors affect asthma management?

Juan Carlos Ivancevich Friday, 18 September 2015 19:37
Open Access
 
Review

Ilaria Baiardini*Francesca SicuroFrancesco BalbiGiorgio Walter Canonica and Fulvio Braido

Abstract

Despite the regular treatment with inhaled corticosteroids (ICS) or ICS plus long-acting beta2-agonists, permits to control de majority of asthmatics, a significant proportion of patients does not respond to this treatment.

This review was aimed to explore the role of psychological factors associated to the unsuccessful fulfilment of optimal levels of asthma control, especially in patients suffering from severe asthma. The results of a Medline search were 5510 articles addressed to different psychological key concepts, constructs and variables. This review will highlight how some selected psychological factors may have a burden on asthma management. Evidences are now available about the link between asthma (in terms of severity and control), some psychological aspects (subjective perception, alexithymia, coping style) and mental health (anxiety, depression). Taking into account this most probably bidirectional influence, a screening of mental symptoms and psychological aspects related to asthma, could lead to plan appropriate interventions to better control asthma and to improve the patient’s well-being.

GAA-INTERASMA Grants

Juan Carlos Ivancevich Tuesday, 01 September 2015 23:43

Carlos E. Baena Cagnani Grant: Best Publication in the Asthma Research and Practice


To honor the memory of its Past President Professor Carlos E. Baena Cagnani, the WCA-2016 will award the “Carlos E. Baena Cagnani Grant” to the Global Asthma Association-INTERASMA Member who has published the Best Article in the Asthma Research and Practice Journal

.

Criteria

•    The applicant should be a GAA-INTERASMA Member the last four (4) years.
•    The applicant should have already published an article in the “Asthma Research and Practice” Journal

Communication Grant


The WCA-2016 will award a Communication Grant to a GAA-INTERASMA Member who has most promoted the Organization and its goals through the Internet and social media.

Criteria

•    The applicant should be a GAA-INTERASMA Member for the last five (5) years.
•    The applicant needs to have already submitted articles for publication in the GAA-INTERASMA website.

Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment

Juan Carlos Ivancevich Tuesday, 25 August 2015 12:53
Open Access
 

Abstract

The acute airway narrowing that occurs as a result of exercise is defined exercise-induced bronchoconstriction (EIB). Most recent guidelines recommend distinguishing EIB with underlying clinical asthma (EIB A ) from the occurrence of bronchial obstruction in subjects without other symptoms and signs of asthma (EIBw A ). EIB has been in fact reported in up to 90 % of asthmatic patients, reflecting the level of disease control, but it may develop even in subjects without clinical asthma, particularly in children, athletes, patients with atopy or rhinitis and following respiratory infections. Both EIB A and EIBw A have peculiar pathogenic mechanisms, diagnostic criteria and responses to treatment and prevention. The use of biomarkers, proteomic approaches and innovative technological procedures will hopefully contribute to better define peculiar phenotypes and to clarify the role of EIB as risk factor for the development of asthma, as well as an occupational disease.

Viewing options

New article has just been published in Asthma Research and Practice

Juan Carlos Ivancevich Thursday, 06 August 2015 12:08
Open Access
Review

Ilaria Baiardini*Francesca SicuroFrancesco BalbiGiorgio Walter Canonica and Fulvio Braido

Author Affiliations

For all author emails, please log on.

Abstract

Despite the regular treatment with inhaled corticosteroids (ICS) or ICS plus long-acting beta2-agonists, permits to control de majority of asthmatics, a significant proportion of patients does not respond to this treatment.

This review was aimed to explore the role of psychological factors associated to the unsuccessful fulfilment of optimal levels of asthma control, especially in patients suffering from severe asthma. The results of a Medline search were 5510 articles addressed to different psychological key concepts, constructs and variables. This review will highlight how some selected psychological factors may have a burden on asthma management. Evidences are now available about the link between asthma (in terms of severity and control), some psychological aspects (subjective perception, alexithymia, coping style) and mental health (anxiety, depression). Taking into account this most probably bidirectional influence, a screening of mental symptoms and psychological aspects related to asthma, could lead to plan appropriate interventions to better control asthma and to improve the patient’s well-being.

23rd World Congress of Asthma - WCA-2016

Juan Carlos Ivancevich Tuesday, 21 July 2015 12:51

Dear colleagues and friends 

It is my privilege and honor to invite you to participate in the 23rd World Congress of Asthma - WCA-2016 in Madrid, Spain, organized by the Asthma Global Association-INTERASMA, from March 12 through March 15, 2016. This congress is supported by the Spanish societies: SEPAR (Sociedad Española de Neumología y Cirugía Torácica), SEAIC (Sociedad Española de Alergología e Inmunología Clínica), SEICAP (Sociedad Española de Alergia, Inmunología Clínica, Asma y Alergia Pediátrica) and Spanish Pediatric Association (AEP) whose members are welcome.

WCA brings together specialists, physicians, and healthcare professionals from all over the world to share valuable scientific knowledge on asthma, ranging from diagnostic and therapeutic tools and techniques to leading-edge research. WCA has been very popular resulting in highly successful well attended congresses with outstanding state-of-the-art scientific programs.

The 23rd World Congress of Asthma - WCA-2016 will not be an exception; we plan to produce a great scientific program once again. The INTERASMA is celebrating its 60th anniversary of uninterrupted education in the field of asthma, making it the most important international asthma and related diseases organization in the world, as well as a reference organization for primary care physicians, healthcare providers and medical students.  

Madrid, the majestic capital of Spain, is one of the most beautiful cities in Europe and it is famous for its rich heritage and culture, hosting important museums with masterpieces of art through centuries of exciting history. Today, Madrid is an economic, financial, administrative and cultural destination, offering great hospitality, infrastructure, great culinary tradition, and a very attractive night life. We look forward to welcoming you in Madrid, Spain, in 2016.

Sincerely, 

 
Professor Giorgio Walter Canonica
President of INTERASMA

http://www.wca-2016.com/ 

Read our inaugural articles and submit your next manuscript

Juan Carlos Ivancevich Tuesday, 21 July 2015 12:36

 

 

  

Editor-in-Chief: Juan Celedón (USA) and Giovanni Passalacqua (Italy)

Submit a manuscript

Editorial Board

Author Instructions

Article Alerts

Dear Colleague,

We are pleased to announce that Asthma Research and Practice has published its first articles with BioMed Central. We hope that you find some of the inaugural articles below of interest.

Inaugural Articles

 

Editorial

Asthma research and practice: a new journey begins

Juan Celedon, Giovanni Passalacqua, Giorgio Canonica

Full Text | PDF

 

Review

Asthma and obesity: mechanisms and clinical implications

Cynthia Baffi, Daniel Winnica, Fernando Holguin

Abstract | Full Text | PDF

 

Research

The patient with rhinitis in the pharmacy. A cross-sectional study in real life

Carlo Lombardi, Eleonora Musicco, Francesco Rastrelli, Germano Bettoncelli, Giovanni Passalacqua, Giorgio Canonica

Abstract | Full Text | PDF

 

Research

Vitamin D supplementation decreases Aspergillus fumigatus specific Th2 responses in CF patients with aspergillus sensitization: a phase one open-label study

Nikki Nguyen, Joseph Pilewski, Juan Celedón, Sivanarayana Mandalapu, Megan Blanchard, Adrienne DeRicco, Elizabeth Hartigan, John Alcorn, Jay Kolls

Abstract | Full Text | PDF

 

About the journal

Asthma Research and Practice will publish articles related to basic asthma research, clinical practice as well as translational research. The journal aims to publish the most recent and relevant information on asthma and related disorders (such as rhinitis, COPD overlapping syndrome, sinusitis).

Reasons to publish in Asthma Research and Practice

 

High quality peer review service

 

Expert international Editorial Board

 

Rapid publication upon acceptance

 

Widest possible global dissemination of your research

 

Keep up to date

Sign up for article alerts to keep up to date with essential research from Asthma Research and Practice.

Sincerely yours,

Juan Celedón and Giovanni Passalacqua

Editors-in-Chief, Asthma Research and Practice

 Follow BioMed Central:      

How to ensure BioMed Central's emails reach your inbox.

You have received this message because you have asked for updates from Asthma Research and Practice.

To change your email preferences please login to: http://www.asthmarp.com/my/details/interests

To unsubscribe as a registrant please visit our journal unsubscribe page.

For further information or enquiries please contact Customer Services at: This email address is being protected from spambots. You need JavaScript enabled to view it. .

BioMed Central Ltd, 236 Gray's Inn Road, London, WC1X 8HB, United Kingdom.

Part of Springer Science+Business Media. Privacy Policy.

BMC19962

 

 

 

 

 

Allergen immunotherapy in asthma; what is new?

Juan Carlos Ivancevich Thursday, 16 July 2015 12:16

Open Access

Review

Giovanni Passalacqua*Anthi RogkakouMarcello Mincarini and Giorgio Walter Canonica

  • *Corresponding author: Giovanni Passalacqua This email address is being protected from spambots. You need JavaScript enabled to view it.

Author Affiliations

For all author emails, please log on.

Abstract

The use and role of allergen immunotherapy (AIT) in asthma is still a matter of debate, and no definite recommendation about this is made in guidelines, both for the subcutaneous and sublingual routes. This is essentially due to the fact that most controlled randomised trials were not specifically designed for asthma, and that objective measures of pulmonary function were only occasionally considered. Nonetheless, in many trials, favourable results in asthma (symptoms, medication usage, bronchial reactivity) were consistently reported. There are also several meta analyses in favour of AIT, although their validity is limited by a relevant methodological heterogeneity. In addition to the crude clinical effect, a disease modifying action of AIT (prevention of asthma onset and long-lasting effects) have been reported. The safety is an important aspect to consider in asthma. Fatalities were rare: in Europe no fatality was reported in the last three decades, as in the United States in the last 4 years. Based on previous surveys, and common sense, uncontrolled asthma is still recognized as the most important risk factor for severe adverse events. On the contrary, there is no evidence that AIT can worsen or induce asthma. According to the available evidence, AIT can be safely used as add-on treatment when asthma is associated with rhinitis (a frequent condition), provided that asthma is adequately controlled by pharmacotherapy. AIT cannot be recommended or suggested as single therapy. When asthma is the unique manifestation of respiratory allergy, its use should be evaluated case by case.

Keywords: 

Allergen immunotherapy; Sublingual immunotherapy; Subcutaneous immunotherapy; Efficacy; Safety; Allergic asthma; Allergic rhinitis; Adverse events 

Viewing options

 

The following new article has just been published in Asthma Research and Practice

Juan Carlos Ivancevich Friday, 03 July 2015 12:28

 

Article alert

Review   

Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment

Bonini M, Palange P

Asthma Research and Practice 2015, 1 :2 (2 July 2015)

Abstract | Full Text | PDF

Asthma Research and Practice: the official journal of Interasma

Juan Carlos Ivancevich Tuesday, 23 June 2015 11:26

Dear Society member,
 
We are very pleased to inform you that
Asthma Research and Practice (ARP) has now officially launched and published its first articles. ARP is the official journal of Interasma – the Global Asthma Association and is led by joint Editors-in-Chief, Juan Celedón (USA) and Giovanni Passalaqua (Italy). The Open Access, peer-reviewed journal aims to spread international awareness and knowledge about the growing burden of asthma by publishing basic, clinical and translational research concerning asthma and related disorders.
 
ARP aims to serve as an international platform for the dissemination of research of interest to pulmonologists, allergologists, primary care physicians and family doctors, ENTs and other health care providers interested in asthma, its mechanisms and comorbidities.
 
You can read all of the publications, including the launch Editorial, on the journal website:
www.asthmarp.com/content. The journal will be published continuously online-only and so
we encourage you to sign up to receive free email alerts to keep up to date with all of the latest research. You can do this by registeringhere.    
 
As an Interasma society member, please do help us spread the word about the journal by encouraging colleagues to submit their manuscripts and by submitting high quality work yourself. Don’t forget we have also have a range of materials available to help you support us in letting people know about the journal,
www.asthmarp.com/about/promote for example if you are attending any meetings relevant to the journal’s scope.
 
Thank you for your support so far, we look forward to working with you to build the success of Asthma Research and Practice!
 
With best wishes,
Juan Celedón, jointEditor-in-Chief
Giovanni Passalacqua, jointEditor-in-Chief
 
Holly Young
Journal Development Editor

BioMedCentral
236 Gray's Inn Road
London, WC1X 8HB
United Kingdom

T: +44 (0)20 3192 2153
E:
This email address is being protected from spambots. You need JavaScript enabled to view it.
W:
www.biomedcentral.com

Interasma on Twitter

Interasma RT @Aller_MD: Top story: Kaléo on Twitter: "Some bullies use words, others use food. Togeth… https://t.co/eOHOsmB43X, see more https://t.…
9hreplyretweetfavorite
Interasma RT @Aller_MD: “Epinephrine Nasal Spray for #Anaphylaxis Shows Promise as Potential Alternative to Auto-Injector” https://t.co/qVsbyMfDuL ht…
9hreplyretweetfavorite
Interasma RT @Aller_MD: “Stress-related disorders were significantly associated with risk of subsequent autoimmune disease” https://t.co/9YWUsJgHWp h…
9hreplyretweetfavorite
Interasma RT @Aller_MD: “A Teledermatology Scale-Up Framework and Roadmap for Sustainable Scaling: Evidence-Based Development” https://t.co/nqPSJpsyg
9hreplyretweetfavorite
Interasma RT @Aller_MD: “Tobacco Product Use Among Youths With and Without Lifetime #Asthmahttps://t.co/wnj8AyUM7Z https://t.co/ydFozighl5
9hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma